Coronary Arteriosclerosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The proinflammatory enzyme myeloperoxidase induces both oxidative modification and nitrosylation of specific residues on plasma and arterial apolipoprotein A-I to render HDL dysfunctional, which results in impaired ABCA1 macrophage transport, the activation of inflammatory pathways, and an increased risk of coronary artery disease.
|
26323267 |
2016 |
Coronary Arteriosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
DNA polymorphisms of apolipoprotein A-I/C-III and insulin genes in familial hypertriglyceridemia and coronary heart disease.
|
3115275 |
1987 |
Coronary Arteriosclerosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Elevated plasma levels of apolipoproteins A1 (apoA1) and B (apoB) are important protective factors and risk factors, respectively, for atherosclerosis and coronary heart disease.
|
11122500 |
2000 |
Coronary Arteriosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
High density lipoprotein, apolipoprotein A-I, and coronary artery disease.
|
10942211 |
2000 |
Coronary Arteriosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The results show for the first time an impaired postprandial lipoprotein removal in a case heterozygote with moderately low HDL cholesterol due to an apolipoprotein A-1 mutation not associated with coronary artery disease.
|
9125314 |
1996 |
Coronary Arteriosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The association between lipoprotein(a) levels, apolipoprotein(a) size and the (TTTTA)(n) polymorphism which is located in the 5' non-coding region of the apo(a) gene was studied in 263 patients with severe coronary heart disease and 97 healthy subjects.
|
11408005 |
2001 |
Coronary Arteriosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Carriers of the apolipoprotein A-I(Milano) (apoA-I(M)) mutant present with very low plasma HDL cholesterol and moderate hypertriglyceridemia, apparently not leading to premature coronary heart disease.
|
11306522 |
2001 |
Coronary Arteriosclerosis
|
0.400 |
Biomarker
|
disease |
CTD_human |
Variants with large effects on blood lipids and the role of cholesterol and triglycerides in coronary disease.
|
27135400 |
2016 |
Coronary Arteriosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
MspI polymorphism at +83 bp in intron 1 of the human apolipoprotein A1 gene is associated with elevated levels of HDL cholesterol and apolipoprotein A1 in nondiabetic subjects but not in type 2 diabetic patients with coronary heart disease.
|
10840998 |
2000 |
Coronary Arteriosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
APOA1/C3/A4/A5 gene cluster is closely involved in lipid metabolism, and its polymorphisms have been associated with coronary heart disease and lipid plasma levels.
|
21712729 |
2011 |
Coronary Arteriosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Recent evidence from a double-blind, randomized study showed that treatment with apolipoprotein A-I Milano (ApoA-I Milano) in a complex with phospholipids produced significant regression of the coronary atheroma burden in patients with acute coronary syndromes.
|
16039279 |
2005 |
Coronary Arteriosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Therefore, HDL-C and apoA1 have been investigated as therapeutic targets for coronary heart disease.
|
24713591 |
2014 |
Coronary Arteriosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Analysis of a new polymorphism in the human apolipoprotein A-I gene: association with serum lipoprotein levels and coronary heart disease.
|
8934336 |
1996 |
Coronary Arteriosclerosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Non-synonymous and regulatory single nucleotide polymorphisms (SNPs) in genes implicated in HDL-C synthesis and metabolism are likely to influence plasma HDL-C, apolipoprotein A-I (apo A-I) levels and severity of coronary atherosclerosis.
|
19878569 |
2009 |
Coronary Arteriosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Human data raised the possibility that coronary heart disease is associated with mutations in the apolipoprotein gene cluster APOA1/C3/A4 that result in multideficiency of cluster-encoded apolipoproteins and hypoalphalipoproteinemia.
|
16497661 |
2006 |
Coronary Arteriosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Apolipoprotein A-I gene polymorphisms: frequency in patients with coronary artery disease and healthy controls and association with serum apo A-I and HDL-cholesterol concentration.
|
2569310 |
1989 |
Coronary Arteriosclerosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Identification of mutations in the ATP binding cassette transporter (ABCA1) gene in patients with Tangier disease, who exhibit reduced HDL cholesterol (HDL-C) and apolipoprotein A1 (apoA1) levels and premature coronary atherosclerosis, has led to the hypothesis that common polymorphisms in the ABCA1 gene could determine HDL-C and apoA1 levels and the risk of coronary atherosclerosis in the general population.
|
11349008 |
2001 |
Coronary Arteriosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
A Pst-I RFLP polymorphism adjacent to the 3' end of the apolipoprotein A-I gene is reported to associate with hypoalphalipoproteinaemia with dominant inheritance in families identified through accelerated coronary heart disease.
|
8096444 |
1993 |
Coronary Arteriosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Amyloid deposits of WT apolipoprotein A-I (apoA-I), the main protein component of high-density lipoprotein, accumulate in atherosclerotic plaques where they may contribute to coronary artery disease by increasing plaque burden and instability.
|
29853648 |
2018 |
Coronary Arteriosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
As the major apoprotein of high density lipoprotein (HDL), apolipoprotein A1 (apo-A1) is generally accepted as a protective factor for coronary artery disease.
|
9523212 |
1998 |
Coronary Arteriosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Apolipoprotein(a) phenotypes, Lp(a) concentration and plasma lipid levels in relation to coronary heart disease in a Chinese population: evidence for the role of the apo(a) gene in coronary heart disease.
|
1541665 |
1992 |
Coronary Arteriosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Apolipoprotein A-I (apoA-I) exerts many potentially anti-atherogenic properties and is therefore attractive for prevention and therapy of coronary heart disease.
|
21930241 |
2011 |
Coronary Arteriosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The ApoA-1 Synthesis Stimulation and intravascular Ultrasound for coronary atheroma Regression Evaluation (ASSURE; NCT01067820) study employed serial intravascular ultrasound (IVUS) measures of coronary atheroma in 281 patients treated with apabetalone or placebo for 26 weeks.
|
30155718 |
2019 |
Coronary Arteriosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Compound heterozygosity for a structural apolipoprotein A-I variant, apo A-I(L141R)Pisa, and an apolipoprotein A-I null allele in patients with absence of HDL cholesterol, corneal opacifications, and coronary heart disease.
|
8840853 |
1996 |
Coronary Arteriosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
ApoA-I related DNA polymorphism in humans with coronary heart disease.
|
2876946 |
1986 |